Filing Flows

Filing Flows › Criteo S.A. (CRTO) › Guidance & outlook

Criteo S.A. (CRTO) guidance and outlook

Criteo S.A. (CRTO) updated its guidance on Nov 4, 2026: EBITDA $105M–$111M for Q4 2026. Criteo S.A.'s 10-Q filed Nov 4, 2026 makes 10 forward-looking statements.

Guidance and outlook

Criteo S.A.: what its forward-looking statements are about (10-Q filed 2026-11-04)Criteo S.A.: what its forward-looking statements are about (10-Q filed 2026-11-04)Other4Demand2Supply chain1Financing1Buybacks & dividends1Capital spending1
10 statements; tone -0.20 (−1 all cautious, +1 all confident); 1 hedged.
Criteo S.A.: outlook statements against the filing beforeCriteo S.A.: outlook statements against the filing beforeConfident1Cautious3

Latest guidance

MetricPeriodRangeChange
EBITDAQ4 2026$105M–$111Mnew

From the earnings release filed Nov 4, 2026 (8-K on EDGAR).

Forward-looking statements, 10-Q filed Nov 4, 2026

Criteo S.A.'s latest quarter

Criteo S.A., Q3 2026: revenue $416M (-11% year over year), operating margin 5.0%, net earnings $5.6M, operating cash flow $56.9M. The chart follows the revenue to costs, profit and cash.

Questions

Did Criteo S.A. raise or lower its guidance?

Criteo S.A. (CRTO) updated its guidance on Nov 4, 2026: EBITDA $105M–$111M for Q4 2026.

What does Criteo S.A. expect?

– Performance Media: This segment encompasses our targeting capabilities and supply and AdTech services. Changes in business expectations, including further reductions in projected revenue or margins, a continued decline in the Company's stock price or market capitalization, or additional information becoming available in subsequent periods could adversely affect the assessment and result in goodwill impairment in future periods. The Company will continue to monitor operating performance, market capitalization and other relevant factors for indicators of potential impairment.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.